Are Psychedelics the New Prozac?
Amidst a national epidemic of opioid abuse, and suicides the need for new therapeutics has gained greater urgency. In it's first step to...
Cybin (CLXPF CYBN) Gets $8.00 Price Target From H.C. Wainwright.
Advancing Multiple Psychedelics in Multiple Indications; Initiating With a Buy and $8 Price Target.
Atai Life Sciences (ATAI) Founder Christian Angermayer Interview.(VIDEO)
Best Psychedelic related interview we've seen yet. Christian states, "I think ultimately, the total addressable market is 100% of the world population!"
I Use Ketamine for Depression – Here’s How It Works.
FREETHINK: When first manufactured as an anesthetic for humans and animals in 1962, doctors had no intention of prescribing ketamine for depression....
Mitesco’s (MITI) CEO Featured In Yahoo News Video.
Michael C. Howe, CEO of Mitesco's 'Good Clinic' and Original Partner of CVS the Acquired 'Minute Clinic' on Yahoo's Finance Channel....
GBT (GTCH) Technologies Looking for Strategic Partners.
GBT Has Opened the Doors for Massive Potential in Minimal Infrastructure Communications.
There are some Artificial Intelligence rocket-scientists...
Citius Pharma (CTXR) $2.15. Price Target of $8.00 Maintained, Post Safety and Efficacy Review.
Investment Banker Buy Rating Maintained: DSMB Gives the Thumbs Up – Data in Early 2022.
CITIUS NEWS ARCHIVE
Ehave (EHVVF) Looks to Power the Psychedelics Revolution
Mental illness will cost the global economy $16 trillion by 2030 due to early-onset and lost productivity, with an estimated 12 billion working days...
Ehave (EVVHF) Hires Institutional Review Board (IRB) As It Solidifies Partnership With Tristar Wellness...
Institutional Review Board (IRB) reviews proposed research protocols to protect human subjects involved in research.
MIAMI, July 09,...
Psychedelic Investor Conferences.
Not Quite as Popular as the Bitcoin 2021 Conference Attended by 12,000 - But Worth Considering!